Picture loading failed.

Anti-IGF1R therapeutic antibody (Pre-made Ganitumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ganitumab a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-231-1mg 1mg 3090
GMP-Bios-ab-231-10mg 10mg 21890
GMP-Bios-ab-231-100mg 100mg 148000
GMP-Bios-ab-231-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-IGF1R therapeutic antibody (Pre-made Ganitumab biosimilar,Whole mAb)
INN Name Ganitumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesAmgen;Millennium;NantWorks;National Cancer Institute (USA);Novartis;Takeda;Takeda Oncology;UCLAs Jonsson Comprehensive Cancer Center
Conditions Approvedna
Conditions ActiveEwing's sarcoma;Solid tumours;Rhabdomyosarcoma
Conditions DiscontinuedBreast cancer;Colorectal cancer;Sarcoma;Small cell lung cancer;Non-small cell lung cancer;Pancreatic cancer;Prostate cancer
Development Techna